Cost-Effectiveness of Alternatives to Allogeneic Blood Transfusion; Reviewing the Available Evidence

  • M. van Hulst
  • Maarten J. Postma
Part of the Developments in Hematology and Immunology book series (DIHI, volume 37)


Major progress has been made during the last decade in the safety of allogeneic blood products. Donor deferral and extended testing for viruses and bacteria substantially reduced risks associated with blood transfusion. The window period of detection is almost closed and any remaining pathogen might in future be eliminated by pathogen inactivation. However, the small risk of complications after blood transfusion still remains a major concern to the general public and health policy makers The perception of these risks and potential judicial consequences cause decision makers to favour implementation of procedures to further improve blood transfusion safety [1]. Besides improving safety of allogeinic blood products itself, risk reduction can be achieved by limiting the number of allogeinic transfusions transfused to the recipient. These conservation strategies comprise autologous transfusion, acute normovolemic hemodilution, use of blood growth factors (erythropoietin), peri-operative cell salvage, artificial blood and development of guidelines for minimal use of blood transfusion [2–4] The utilisation of conservation technologies varies between and within countries [5]. From a pharmaco-economic point of view it is relevant to investigate whether monetary benefits of averted transfusion complications by conservation techniques surpass the costs, or, whether the marginal net costs justify the health gains achieved.


Recombinant Human Erythropoietin Allogeneic Transfusion Autologous Transfusion Preoperative Autologous Blood Donation Acute Normovolemic Hemodilution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Finucane ML, Slovic P, Mertz CK. Public perception of the risk of blood transfusion. Transfusion 2000; 40: 1017–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Practice strategies for elective red blood cell transfusion. American College of Physicians. Ann Intern Med. 1992; 116: 403–06.Google Scholar
  3. 3.
    Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts-blood conservation. N Engl J Med 1999; 340: 5 2533.Google Scholar
  4. 4.
    Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996; 84: 732–47.CrossRefGoogle Scholar
  5. 5.
    Fergusson D, Blair A, Henry D, et al. Technologies to minimize blood transfusion in cardiac and orthopedic surgery. Results of a practice variation survey in nine countries. International Study of Peri-operative Transfusion (ISPOT) Investigators. Int J Technol Assess Health Care 1999; 15: 717–28.PubMedGoogle Scholar
  6. 6.
    Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care 1993; 9: 26–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997.Google Scholar
  8. 8.
    Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.Google Scholar
  9. 9.
    Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1172–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics. 1997; 11: 159–68.PubMedCrossRefGoogle Scholar
  12. 12.
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253–58.PubMedCrossRefGoogle Scholar
  13. 13.
    Hjelmgren J, Berggren F, Andersson F. Health economic guidelines-similarities, differences and some implications. Value Health 2001; 4: 225–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Weinstein MC, Siegel JE, Garber AM, et al. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ. 1997; 6: 505–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ. 1997; 6: 253–59.PubMedCrossRefGoogle Scholar
  16. 16.
    Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 1997; 6: 511–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Jefferson T, Demicheli V, Mugford M. Elementary Economic Evaluation in Health Care. London: BMJ Publishing Group, 1996.Google Scholar
  18. 18.
    Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsij PG, Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993; 33: 544–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Birkmeyer JD, AuBuchon J, Littenberg B, et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg. 1994; 57: 161–69.PubMedCrossRefGoogle Scholar
  20. 20.
    Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med. 1995; 332: 719–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Huber TS, McGorray SP, Carlton LC, et al. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. J Vasc Surg. 1997; 25: 984–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Kilgore ML,.Pacifico AD. Shed mediastinal blood transfusion after cardiac operations: a cost-effectiveness analysis. Ann Thorac Surg. 1998; 65: 124–854.Google Scholar
  23. 23.
    Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998; 78: 781–87.PubMedCrossRefGoogle Scholar
  24. 24.
    Coyle D, Lee KM, Fergusson DA, Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics. 2000; 18: 161–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Sonnenberg FA, Gregory P, Yomtovian R, et al. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion 1999; 39: 808–17.PubMedCrossRefGoogle Scholar
  26. 26.
    Marchetti M,.Barosi G. Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery. Transfusion 2000; 40: 673–81.CrossRefGoogle Scholar
  27. 27.
    Jackson BR, Umlas J, AuBuchon J. The cost-effectiveness of postoperative recovery of RBCs in preventing transfusion-associated virus transmission after joint arthtoplasty. Transfusion 2000; 40: 1063–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Coyle D, Lee KM, Fergusson DA, Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med 1999; 9: 21–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Goodnough LT, Monk TG, Brecher ME. Autologous blood procurement in the surgical setting: lessons learned in the last 10 years. Vox Sang 1996; 71: 133–41.PubMedCrossRefGoogle Scholar
  30. 30.
    Faught C, Wells P, Fergusson D, Laupacis A. Adverse effects of methods for minimizing perioperative allogeneic transfusion: a critical review of the literature. Transfus Med Rev 1998; 12: 206–25.PubMedCrossRefGoogle Scholar
  31. 31.
    Vamvakas EC,.Carven JH. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: effect of the length of storage of transfused red cells. Transfusion 1999; 39: 701–10.CrossRefGoogle Scholar
  32. 32.
    Vamvakas EC,.Carven JH. Length of storage of transfused red cells and postoperative morbidity in patients undergoing coronary artery bypass graft surgery. Transfusion 2000; 40: 101–09.CrossRefGoogle Scholar
  33. 33.
    Vamvakas EC,.Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97: 1180–95.CrossRefGoogle Scholar
  34. 34.
    Leal-Noval SR, Rincon-Ferrari MD, Garcia-Curiel A, Herruzo-Aviles A, Camacho-Larana P, Garnacho-Montero J et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest 2001; 119: 1461–68.PubMedCrossRefGoogle Scholar
  35. 35.
    Chelemer SB, Prato BS, Cox PM, Jr., O’Connor GT, Morton JR. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg 2002; 73: 138–42.PubMedCrossRefGoogle Scholar
  36. 36.
    D’Ambra MN, Gray RJ, Hillman R, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64: 1686–93.PubMedCrossRefGoogle Scholar
  37. 37.
    Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood 1997; 89: 411–18.PubMedGoogle Scholar
  38. 38.
    Goodnough LT, Despotis GJ, Parvin CA. Erythropoietin therapy in patients undergoing cardiac operations. Ann.Thorac.Surg. 1997; 64: 1579–80.PubMedCrossRefGoogle Scholar
  39. 39.
    Muller-Breitkreutz K. Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. EPFA Working Group on Quality Assurance. Vox Sang. 2000; 78: 149–57.CrossRefGoogle Scholar
  40. 40.
    Loubiere S, Rotily M, Durand-Zaleski I, Costagliola D. Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vox Sang. 2001; 80: 199–204.PubMedCrossRefGoogle Scholar
  41. 41.
    Pereira A. Deleterious consequences of allogenic blood transfusion on postoperative infection: really a transfusion-related immunomodulation effect? Blood 2001; 98: 498–500.PubMedCrossRefGoogle Scholar
  42. 42.
    Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13: 716–17.PubMedCrossRefGoogle Scholar
  43. 43.
    Michel BC, van Hout BA, Bonsel GJ. Assessing the benefits of transplant services. Baillieres Clin Gastroenterol 1994; 8: 411–23.PubMedCrossRefGoogle Scholar
  44. 44.
    Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369–90.PubMedCrossRefGoogle Scholar
  45. 45.
    Al MJ, Koopmanschap MA, van Enckevort PJ, Geertsma A, et al. Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis. Chest 1998; 113: 124–30.PubMedCrossRefGoogle Scholar
  46. 46.
    Hoffer S, Berardino F, Smith J, Rubin S. Economic Values for Evaluation of FAA Investment and Regulatory Decisions. Washington, DC: Federal Aviation Administration, Office of Aviation Policy, Plans, and Management Analysis Publication FAA-APO-98–8, 1998.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2002

Authors and Affiliations

  • M. van Hulst
    • 1
    • 2
  • Maarten J. Postma
    • 1
  1. 1.Department of Social PharmacyPharmaco-epidemiology and Pharmacotherapy Groningen University Institute for Drug Exploration / University of Groningen Research Institute of Pharmacy (GUIDE/GRIP)GroningenNL
  2. 2.Department of Clinical Pharmacy and ToxicologyMartini HospitalGroningenNL

Personalised recommendations